ReviewCancer science2026
circMAN1A2 as an Isoform-Resolved Circular RNA Hub in Cancer.
Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) are covalently closed transcripts generated by spliceosome-mediated back-splicing. Their high stability and tissue-, cell-state-, and disease-context specificity support roles as cancer regulators and biomarkers. circMAN1A2, derived from the MAN1A2 locus, is recurrently dysregulated across malignancies. This review aims to summarize current knowledge of circMAN1A2 biology and evaluates its mechanistic and translational relevance in cancer. Emerging evidence indicates that circMAN1A2 should be considered an isoform-resolved RNA hub. Alternative circularization generates multiple isoforms, whereas cancer tissues often show dominance of a predominantly expressed isoform. Functionally, circMAN1A2 extends beyond microRNA sponging to protein binding, proteostasis regulation, and direct circRNA-mRNA pairing mediated by the back-splice junction. Its biological effects are highly context dependent: circMAN1A2 promotes oncogenic phenotypes in several epithelial cancers, but can suppress glioblastoma by inducing ferroptosis and remodeling the immune microenvironment. We integrate evidence on circMAN1A2 isoforms, biogenesis, interactome modules, and cancer-type-specific phenotypes; highlight experimental and quantitative limitations, particularly in competing endogenous RNA models; and propose a translational route for biomarker development and therapeutic targeting, including back-splice-junction-directed oligonucleotides and isoform restoration. Reproducible, isoform-specific standards will be essential for defining the clinical actionability of circMAN1A2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.